Publications (81) View all
-
Article: Autoantibodies in autoimmune hepatitis: Anti-liver kidney microsome type 1 (anti-LKM1) and anti-liver cytosol type 1 (anti-LC1) antibodies.
Catherine Johanet, Eric BallotGastroentérologie Clinique et Biologique 03/2013; · 0.80 Impact Factor -
Article: Autoantibodies in autoimmune hepatitis: Anti-asialoglycoprotein receptor (anti-ASGPR) antibodies.
Yannick Chantran, Eric Ballot, Catherine JohanetGastroentérologie Clinique et Biologique 09/2012; · 0.80 Impact Factor -
Article: Immunoproteomic analysis of potentially severe non graft versus host disease hepatitis following allogenic bone marrow transplantation.
Elvire Beleoken, Rodolphe Sobesky, Jean-Pierre Le Caer, François Le Naour, Mylène Sebagh, Nicolas Moniaux, Bruno Roche, Mohammad Zahid Mustafa, Catherine Guettier, Catherine Johanet, Didier Samuel, Jean-Henri Bouhris, Jean-Charles Duclos-Vallee, Eric Ballot[show abstract] [hide abstract]
ABSTRACT: The development of potentially severe non graft-versus-host disease (GVHD) hepatitis resembling autoimmune hepatitis (AIH) has been reported exceptionally following bone marrow transplantation (BMT). The purpose of this study was to better characterize this form of hepatitis, particularly through the identification of auto-antigens recognized by patient sera. PATIENTS AND METHODS.: Five patients who received an allogeneic BMT for the treatment of haematological diseases developed liver dysfunctions with histological features suggestive of AIH. Before and during the onset of hepatic dysfunction, sera were tested on immunoblots performed with cytosolic, microsomal, mitochondrial and nuclear proteins from rat liver homogenate and resolved by two-dimensional electrophoresis. Antigenic targets were identified by mass spectrometry. RESULTS.: During the year that followed BMT, all patients presented with GVHD. Acute hepatitis then occurred after the withdrawal, or during the tapering, of immunosuppressive therapy. At that time, no patients had a history of liver toxic drug absorption, patent viral infection or any histopathological findings consistent with GVHD. Immunoreactive spots stained by sera collected at the time of hepatic dysfunction were more numerous and more intensely expressed than those stained by sera collected before. Considerable patient-dependent pattern heterogeneity was observed. Among the 259 spots stained exclusively by sera collected at the time of hepatitis, a total of 240 spots were identified, corresponding to 103 different proteins. Twelve of them were recognized by sera from three patients. CONCLUSION.: This is the first immunological description of potentially severe non GVHD hepatitis occurring after BMT, determined using a proteomic approach and enabling a discussion of the mechanisms that transform an alloimmune reaction into an autoimmune response. Any decision to withdraw immunosuppression after allogeneic BMT should be made with caution. (HEPATOLOGY 2012.).Hepatology 08/2012; · 11.66 Impact Factor -
Article: Autoantibodies in autoimmune hepatitis: Antinuclear antibodies (ANA).
Catherine Johanet, Elvire Beleoken, Eric BallotGastroentérologie Clinique et Biologique 04/2012; 36(4):394-6. · 0.80 Impact Factor -
Article: Auto-antibodies in autoimmune hepatitis: anti-soluble liver antigen (SLA).
Catherine Johanet, Eric BallotGastroentérologie Clinique et Biologique 02/2012; 36(3):244-6. · 0.80 Impact Factor